Alpha Cognition Inc. (ACOG): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$22.60M
Year ended 2025-12-31
2023-12-31: -$9.85M2024-12-31: -$11.93M2025-12-31: -$22.60M-$22.60M
2023-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$22.60Mn/m2026-03-31, From 2025-01-01
2024-12-31-$11.93Mn/c2026-03-31, From 2024-01-01
2023-12-31-$9.85Mn/a2025-03-31, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Alpha Cognition Inc. (ACOG)2025-12-31-$22.60Mn/m
TScan Therapeutics, Inc. (TCRX)2025-12-31-$132.91Mn/m
Curis Inc (CRIS)2025-12-31-$5.54Mn/m
Caribou Biosciences, Inc. (CRBU)2025-12-31-$144.70Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$35.92Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$134.80Mn/m
DBV Technologies S.A. (DBVT)2025-12-31-$144.07Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$90.85Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$5.31Mn/m

Compare ACOG, TCRX, CRIS, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗